{
    "clinical_study": {
        "@rank": "132754", 
        "arm_group": {
            "arm_group_label": "Lenalidomide and Rituximab", 
            "arm_group_type": "Experimental", 
            "description": "Lenalidomide 20 mg once daily on days 1-21 of 28 days cycle for up to 6 courses and Rituximab 375 mg/m2 at day 14 of every course."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether lenalidomide in association with rituximab\n      is effective in the treatment of patients with indolent non follicular NHL relapsed after\n      >=2, but less than 4 prior lines of (immuno)chemotherapy."
        }, 
        "brief_title": "Lenalidomide Plus Rituximab (R) in Non Follicular NHL", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Indolent Non Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "Single arm, multicenter, open-label study divided in two phases: 1. Induction phase; 2.\n      Follow-up phase. Enrolled patients will start the induction phase and receive the courses of\n      R-Lenalidomide. At the end of the third cycle of R-Lenalidomide (week 12 of the study), the\n      patients will be evaluated for tumor response (complete assessment); the patients with\n      Progressive Disease (PD) will be withdrawn of the study. Two weeks after the end last\n      courses of R-Lenalidomide (week 26 of the study) patients will be evaluated for tumor\n      response (complete assessment). Patients with Complete Response (CR) and Partial Response\n      (PR), and with a stable disease will undergo the follow up phase, while patients with PD\n      will be withdrawn of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological confirmed diagnosis of B-Cell non follicular NHL according to REAL/WHO\n             Classification: small lymphocytic lymphoma, lymphoplasmacytic lymphoma/Waldenstrom\n             macroglobulinemia, nodal marginal zone lymphoma,  splenic marginal zone lymphoma,\n             extranodal non-gastric marginal zone lymphoma\n\n          -  Availability of tissue biopsy mandatory when suspected pathological sites  (nodal or\n             extranodal) are easily accessible  and in presence of  extranodal non-gastric\n             marginal or nodal marginal zone lymphoma diagnosis. In the other cases bone marrow\n             biopsy, when representative, may be considered sufficient for defining lymphoma\n             histotype\n\n          -  Disease relapsing after >=2, but less than 4 prior lines of (immuno)chemotherapy. At\n             least one of previous treatment had to include rituximab\n\n          -  Presence of at least one of the following criteria for the definition of active\n             disease: systemic symptoms, bulky disease, progressive marrow failure and/or\n             splenomegaly and/or lymph adenopathy\n\n          -  Age 18-75\n\n          -  Life expectancy > 6 months\n\n          -  Eastern Cooperative Oncology Group (ECOG) <=2\n\n          -  Left ventricular ejection fraction (LVEF) >=45%\n\n          -  Creatinine clearance >= 50 mL/min calculated by Cockcroft-Gault estimation; patients\n             with creatinine clearance >= 30 and < 50 mL/min, at physician discretion could enter\n             the study starting at lenalidomide dose level -2 (10 mg)\n\n          -  Total bilirubin up to 2 x upper limit of normal(ULN). Total bilirubin values higher\n             than 2 x ULN are admitted if related to localization of the disease\n\n          -  Alkaline phosphatase up to 2 x ULN and transaminases up to 3 x ULN\n\n          -  Female and male patients must agree to participate in pregnancy prevention program\n             signing informed Consent (paragraph 5.4.)\n\n          -  Written informed Consent\n\n        Exclusion Criteria:\n\n          -  Previously untreated patients\n\n          -  Patients with diagnosis of  typical Chronic Lymphocytic Leukemia (CLL)\n\n          -  Women and men not agreeing to take adequate contraceptive precautions during and for\n             at least 4 weeks after cessation of therapy\n\n          -  Pregnant or lactating women\n\n          -  History of other malignancies within 3 years prior to study entry except for\n             adequately treated carcinoma in situ of the cervix or basal or squamous cell skin\n             cancer, low grade, early stage localized prostate cancer treated surgically with\n             curative intent, good prognosis ductal carcinoma in situ (DCIS) of the breast treated\n             with lumpectomy alone with curative intent\n\n          -  Active bacterial, viral or fungal infection requiring systemic therapy\n\n          -  Concurrent co-morbid medical condition which might exclude administration of therapy\n\n          -  Cardiac insufficiency (NYHA grade III/IV)\n\n          -  Myocardial infarction within 6 months of entry on the study\n\n          -  Severe chronic obstructive pulmonary disease with hypoxemia\n\n          -  Severe diabetes mellitus difficult to control with adequate insulin therapy\n\n          -  Hypertension that is difficult to control\n\n          -  Creatinine clearance < 30 mL/min calculated by Cockcroft-Gault estimation\n\n          -  Absolute neutrophil count (ANC) <= 1 x 109/L, unless due to lymphoma involvement and\n             not responding to 5 days of Granulocyte colony-stimulating factor (G-CFS) treatment\n\n          -  Platelets count <=75.000/mm3, unless due to lymphoma involvement\n\n          -  HIV and Hepatitis B virus (HBV) positivity\n\n          -  Hepatitis C virus (HCV) positivity in presence of high level of virus replication and\n             Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) > x 2.5 ULN\n\n          -  Central nervous system (CNS) involvement by lymphoma\n\n          -  Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins\n\n          -  Any other co-existing medical or psychological condition that would preclude\n             participation in the study or compromise ability to give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830478", 
            "org_study_id": "INFL08"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lenalidomide and Rituximab", 
                "description": "Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles", 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug", 
                "other_name": "Revlimid"
            }, 
            {
                "arm_group_label": "Lenalidomide and Rituximab", 
                "description": "Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug", 
                "other_name": "Mabthera"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rituximab", 
                "Thalidomide", 
                "Lenalidomide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Modena", 
                    "country": "Italy", 
                    "state": "MO", 
                    "zip": "41124"
                }, 
                "name": "Centro Oncologico Modenese"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Lenalidomide in Combination With Rituximab (R) for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL).", 
        "overall_official": {
            "affiliation": "Gruppo Italiano Studi Linfomi", 
            "last_name": "Stefano Sacchi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluate the efficacy in term of Overall Response Rate (Complete Response + Partial Response) and Tumour Control Rate (Complete Response + Partial Response + Stable Disease)", 
            "measure": "Assess the efficacy", 
            "safety_issue": "No", 
            "time_frame": "Two weeks after the completion of Rituximab + Lenalidomide"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830478"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The safety will be evaluated on the basis of recorded toxicities graded on a scale of 1 to 5 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0", 
            "measure": "Assess the safety", 
            "safety_issue": "Yes", 
            "time_frame": "From start of treatment for all follow up period (18 months)"
        }, 
        "source": "Gruppo Italiano Studio Linfomi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gruppo Italiano Studio Linfomi", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2009", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}